SIM - Worlds First Instrumented Incontinence Assessment Device - "An Investment in the Care of Ageing People" - Worlds First Instrumented ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
SIM™ - Worlds First Instrumented Incontinence Assessment Device “An Investment in the Care of Ageing People” Presented by: Philippa Lewis – CEO March 2014 PAGE 1 | © Simavita Limited | Commercial in Confidence
Disclaimer This document has been prepared by Simavita Limited (Simavita) and comprises written materials/slides for a presentation concerning Simavita. This presentation has been prepared by Simavita for professional investors. The information contained in this presentation is for information purposes only and does not constitute an offer or solicitation to sell or to issue, or arrange to sell or issue, securities or other financial products. Any such offer or solicitation will be made only by means of a confidential information memorandum and in accordance with applicable securities and other laws. The information contained in this presentation is not investment or financial product advice, is not intended to be used as the basis for making an investment decision, and no specific recommendations are intended. The presentation has been prepared without taking into account the investment objectives, financial situation or particular need of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in the presentation. To the maximum extent permitted by law, none of Simavita, its related companies and their respective directors, employees or advisers, nor any other person accepts any liability, including, without limitation, any liability arising out of fault . Certain statements in this presentation are forward looking statements. These forward looking statements speak only as at the date of this presentation. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements. No representation, warranty or assurance (express or implied) is given or made by Simavita that the forward looking statements contained in this presentation are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct . Except for any statutory liability which cannot be excluded, each of Simavita, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom. PAGE 2 | © Simavita Limited | Commercial in Confidence
Simavita Investment Case “An Investment in the Care of Ageing People” • Aging global population – an investment “mega trend” • Commercialized product – FDA clearance in place • Digitized healthcare – reduced costs and superior accuracy • Innovative, disruptive technology – smarter, better, cheaper • Consumer choice – improved quality of care • US Distribution Agreement in place for SIM™ • Other global distribution discussions advancing • Global first mover advantage – strong patent protection PAGE 3 | © Simavita Limited | Commercial in Confidence
Incontinence by Numbers
Simavita’s Global Market
• 240 Million People in the western world are incontinent
• 15+ Million Incontinence assessments /year
• $6 Billion Assessment labor costs /year (nursing homes only)
• $9 Billion Continence products sold /year
• #2 Nursing home cost (after labor)
• 25%+ Total % of labor attributed to incontinence management in aged
care facilities
• 70%+ Over 70% of residents in aged care are incontinent
PAGE 4 | © Simavita Limited | Commercial in Confidence
What is SIM™ SIM™ replaces inaccurate & labor intensive manual methods PAGE 5 | © Simavita Limited | Commercial in Confidence PAGE 5 | © Simavita Limited | Commercial in Confidence
Over USD 31m Spent on Research, Development and Commercialisation • Incubator project from 1996 • First clinical trial 2004 • Philippa Lewis joins Simavita in 2007 • 40 sites in Australia used for “in market” product development, commercialisation and early sales • US Distribution commencing by Medline in Q1 2014 • Global distribution discussions advancing in Canada and the EU PAGE 6 | © Simavita Limited | Commercial in Confidence PAGE 6 | © Simavita Limited | Commercial in Confidence
SIM™ World’s first Integrated and Instrumented Incontinence Assessment PAGE 7 | © Simavita Limited | Commercial in Confidence PAGE 7 | © Simavita Limited | Commercial in Confidence
SIM™ 72 Hour Bladder Chart SIMTM provides “Big Data” PAGE 8 | © Simavita Limited | Commercial in Confidence PAGE 8 | © Simavita Limited | Commercial in Confidence
SIM™ Summary observations Clinical guidelines PAGE 9 | © Simavita Limited | Commercial in Confidence PAGE 9 | © Simavita Limited | Commercial in Confidence
Published Peer Reviewed Research Statistically Significant (Journal of Clinical Nursing) Effective continence management can significantly improve the patients’ health outcome through early detection and management of urinary incontinence reducing a range of associated problems including: • Reduce risk of urinary tract infections, • Reduce risk of skin breakdown, • Reduce risk of falls and adverse or aggressive behaviours. Positive continence management leads to patient’s regaining independence, improved socialisation and overcomes depression associated with incontinence. Study outcome; Using the SIM™ caregivers were able to greatly improve incontinence management in a short-time frame - within 2 weeks. • Reduced volume of urine voided into continence aids • Increased number of successful toileting events • Increased adherence to urinary continence care plans by staff PAGE 10 | © Simavita Limited | Commercial in Confidence
Facility Cost Reduction
The Australian Experience
INCONTINENCE PRODUCT Facility statistics post
COST REDUCTION
25% SIM™ implementation.
44 sites total of 2,367
beds
WASTE COST & LANDFILL
REDUCTION
23%
EFFECTIVE TOILETING
IMPROVEMENT
21%
0% 20% 40% 60% 80% 100%
PAGE 11 | © Simavita Limited | Commercial in Confidence
PAGE 11 | © Simavita Limited | Commercial in ConfidenceSignificant Financial Benefits
And Improved Quality of Care
Supports the Key Revenue Drivers for
Residential Aged Care Facilities
• Reputation/Occupancy
• Government Funding
Delivers proven Cost savings
• Labor
• Consumables
• Time management
• Waste
Generates Critical Information for;
• Care Plans, Toileting, Staff Rostering,
Product Prescription, Undiagnosed
Related Conditions
Significant Improvement in Quality of Care
PAGE 12 | © Simavita Limited | Commercial in ConfidencePatient Benefits
Person centered evidence based
• Less distress and physical
intervention during assessment
• Right product selection (pads)
• Increased socialisation
• Less challenging and aggressive
behaviours
• Less toileting
• Improved skin integrity – less ulcers
• Less falls
• Co-related conditions are identified
and treated more quickly
PAGE 13 | © Simavita Limited | Commercial in ConfidenceStrong IP
Proprietary Technology:
• Sensors
• Algorithms
• Incontinence management software and methods
• Proprietary incontinence patient databank
• Easy-to-use interface to complex data
Broad and deep Patent Portfolio:
• 8 patent families; numerous independent claims
• 3 granted patents; 2 Australia, 1 US and Japan
- global coverage pending
• Global exclusive license to two CSIRO patent portfolios
• High value patenting fields: Incontinence management methods; other
clinical applications; algorithms and software; manufacturing methods
PAGE 14 | © Simavita Limited | Commercial in ConfidenceUS Market
The Costs of Continence Management
• Long Term Care facilities total 2,700,000 beds
• Urinary Incontinence costs $7,300 per bed per annum in labour alone1
• Or $19.9 billion based on 2,700,000 institutional beds
• SIM™ reduces labour and other costs and improves occupancy
• SIM results in a net savings of around $1,580 per bed per annum
• Community Care is estimated to be 170% larger than institutional care2
• Medical Inflation has averaged 3.68% since 2003 against 2.38% for
standard CPI3
1. Labour Costs associated with Urinary Incontinence in long –term care facilities (Shih YC et all 2003)
2. Costs of Urinary Incontinence and overactive bladder in the United States: a comparative study (Hu TW et all 2004)
3. BSL Data Series - Consumer Price Index - Medical Care (2000-2013)
PAGE 15 | © Simavita Limited | Commercial in ConfidenceMEDLINE US Distribution Partner • Medline Industries Inc., head office, Chicago, Illinois • Revenue USD 7b+ 2012, #79 private company Forbes • 1100 sales reps and 37 distribution centers • Largest privately held manufacturer and distributor of healthcare products in the US • Leading provider of adult incontinence products to the US healthcare market • High quality training through “Medline University” • Manufactures incontinence products in Atlanta, Georgia PAGE 16 | © Simavita Limited | Commercial in Confidence
US Market Simavita Revenue Model
Per Site
Revenue model for SIM™ in US Long Term Care
• One off Software Sale
• Annual Software Licence
• Sale of Hardware
• Recurring Annual Sensor Sales
• Estimated revenue per site $15k-$70k per site dependant upon size,
occupancy, frequency of assessments and consumable used per
assessment
PAGE 17 | © Simavita Limited | Commercial in ConfidenceLong Term Care Facilities Global Revue - Commencement of Assessments PAGE 18 | © Simavita Limited | Commercial in Confidence PAGE 18 | © Simavita Limited | Commercial in Confidence
SIM™ Licensing and Royalty Applications
Product spin outs
2016-17
• Application D Royalty
• Application C Royalty
2015-16
• Application B Royalty
• Application A Royalty
• Retail Everyday Royalty
2014-15 • Com Care Everyday Royalty
• LTC Everyday Royalty
2013-14 • Data Management
• Com Care
Current Assessments
Each product is developed with partner and sold
• LTC Assessments
through their distribution channels. Product
development and license fee paid to Simavita.
Generates revenue through Royalty
PAGE 19 | © Simavita Limited | Commercial in ConfidenceSimavita Limited Corporate Snapshot Cash on hand $7m Monthly burn $500K Growing revenue Australia, US Listed on TSXV, Canada 6th December 2013, Code SV Dual Listed on ASX, Australia 20th February 2014, Code SVA Number of Shares on Issue 58,766,653 Share Price AUD$0.41 Market Capitalisation AUD$24.1m Options/Warrants on Issue 9,186,207 Strike price s AUD$0.41 – 0.82, Expiry 3-5 years PAGE 20 | © Simavita Limited | Commercial in Confidence
Contacts Australia Philippa Lewis Jane Lowe – Investor Relations CEO Account Director Simavita Limited Buchan's Consulting Mobile + 61 415 245 159 Mobile +61 411 117 774 Email plewis@simavita.com Email jlowe@buchanwe.com.au Website www.simavita.com Website www.buchanwe.com.au PAGE 21 | © Simavita Limited | Commercial in Confidence
Thank you PAGE 22 | © Simavita Limited | Commercial in Confidence
You can also read
